Curve Therapeutics secures £40.5m Series A funding to advance oncology candidates into human trials
Pfizer Ventures led the financing round alongside Columbus Venture Partners and British Patient Capital.
Share allotment filed at Companies House
Southampton-based biotech startup developing an intracellular screening platform to tackle complex cancer targets.
Curve Therapeutics, a Southampton-based biotech startup, has raised £40.5m in a Series A financing round to advance its cancer drug candidates toward human trials.
The round was led by Pfizer Ventures, with participation from Columbus Venture Partners, British Patient Capital, and returning investors Advent Life Sciences and Epidarex Capital.
The capital will be directed toward pushing the company's lead assets into clinical evaluation and expanding its proprietary Microcycle drug discovery platform.
From the founder
"This financing will enable us to expand our team, progress our lead assets into the clinic and expand our drug discovery platform. We welcome our new investors alongside our existing strong syndicate and look forward to working together to take Curve to its next stage of growth."
Simon Kerry
Chief Executive Officer at Curve Therapeutics
Use of funds
- 01Fund research and development
- 02Grow the team
- 03Continue product development
Investors
Pfizer Ventures
Columbus Venture Partners
British Patient Capital
Advent Life Sciences
Epidarex Capital
Categories
About the company
Curve Therapeutics
Curve Therapeutics develops a Microcycle platform for intracellular cancer drug discovery.